Diagnostic Utility of Otosight Middle Ear Scope
Diagnostic Utility of the Otosight Middle Ear Scope in Acute Otitis Media
1 other identifier
observational
165
1 country
1
Brief Summary
Evaluate clinic workflow impact of OtoSight use for patients seen in the pediatric otolaryngology clinic.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Feb 2023
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 17, 2022
CompletedFirst Posted
Study publicly available on registry
December 7, 2022
CompletedStudy Start
First participant enrolled
February 21, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 29, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2025
CompletedOctober 31, 2024
October 1, 2024
4 months
November 17, 2022
October 29, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Exam Completion Rate
Compare the successful exam completion rate of these three diagnostic tools. For the Otosight device: presence or absence of visible tympanic membrane, and presence or absence of graph indicating fluid/no fluid in the middle ear. For tympanogram: presence or absence of interpretable tracing indicating normal tympanic membrane movement, retracted tympanic membrane, or no movement of tympanic membrane. For the Otoscope: success is visualization of the tympanic membrane versus unable to see tympanic membrane.
6 months
Detection of middle ear fluid
Compare the detection of middle ear fluid (versus no fluid) of these diagnostic tools.
6 months
Categorization of middle ear fluid
Compare the categorization of middle ear fluid (purulent vs. serous vs mucoid) of these diagnostic tools.
6 months
Secondary Outcomes (1)
Timed Evaluation of Clinic Flow
6 months
Study Arms (1)
Otosight, Otoscope, and Tympanogram
Prospective study using a convenience sample. There will be no group assignment or randomization. There is no intervention planned and therefore, no placebo group or use of controls.
Interventions
The OtoSight Middle Ear Scope is intended for use as an imaging tool for real-time visualization of the human tympanic membrane and fluid or air within the middle ear space. In the presence of middle ear fluid, the OtoSight Middle Ear Scope is used to visualize the fluid density. The OtoSight Middle Ear Scope is also used to provide surface images of the ear canal and tympanic membrane. It is indicated for use in children and adults.
Eligibility Criteria
Patients aged 6 months to 12 years old who are seen in the outpatient Otolaryngology clinic at Texas Children's Hospital main and west campuses who have no history of ear tube placement.
You may qualify if:
- Patients aged 6 months to 12 years old who are seen in the outpatient Otolaryngology clinic at Texas Children's Hospital main and west campuses.
You may not qualify if:
- Patients who have a history of ear tube placement
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Texas Children's Hospital
Houston, Texas, 77030, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Anna Messner, MD
Baylor College of Medicine
- STUDY CHAIR
Yi-Chun Liu, MD
Baylor College of Medicine
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
November 17, 2022
First Posted
December 7, 2022
Study Start
February 21, 2023
Primary Completion
June 29, 2023
Study Completion
June 30, 2025
Last Updated
October 31, 2024
Record last verified: 2024-10
Data Sharing
- IPD Sharing
- Will not share
No one besides the PI, the study staff, the IRB and the sponsor will have access to identifiable research data.